• Explore /
  • Poster
  • / Two phase III studies comparing 6 months of either mFOLFOX6 or XELOX with 3 months of the same regimen as adjuvant chemotherapy in patients with completely resected stage III colon cancer (ACHIEVE) or high-risk stage II colon cancer (ACHIEVE-2).

Two phase III studies comparing 6 months of either mFOLFOX6 or XELOX with 3 months of the same regimen as adjuvant chemotherapy in patients with completely resected stage III colon cancer (ACHIEVE) or high-risk stage II colon cancer (ACHIEVE-2).

Abstract Poster

Authors

null

Takayuki Yoshino

National Cancer Center Hospital East, Chiba, Japan

Takayuki Yoshino , Toshiaki Watanabe , Masaki Mori , Atsushi Ohtsu , Tsunekazu Mizushima , Kentaro Yamazaki , Eiji Sunami , Kuniaki Shirao , Atsushi Sato , Satoshi Morita , Takeharu Yamanaka , Axel Grothey , Daniel J. Sargent , Junichi Sakamoto , Shigetoyo Saji

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Clinical Trial Registration Number

UMIN 000008543 and UMIN 000013036

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3655)

DOI

10.1200/jco.2014.32.15_suppl.tps3655

Abstract #

TPS3655

Poster Bd #

114B

Abstract Disclosures

Similar Posters

First Author: Toshiaki Shichinohe

First Author: Masato Nakamura

First Author: Susumu Sogabe

First Author: Hiroo Ishida